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Background: Pathogenesis of intraventricular hemorrhage (IVH) in premature infants is multifactorial. Little is
known about the impact of genetic variants in the vitamin K-dependent coagulation system on the development
of IVH.
Methods: Polymorphisms in the genes encoding vitamin K epoxide reductase complex 1 (VKORC1 -1639G>A) and
coagulation factor 7 (F7 -323Ins10) were examined prospectively in 90 preterm infants <32 weeks gestational age
with respect to coagulation profile and IVH risk.
Results: F7-323Ins10 was associated with lower factor VII levels, but not with individual IVH risk. In VKORC1-wildtype
infants, logistic regression analysis revealed a higher IVH risk compared to carriers of the -1639A allele. Levels of
the vitamin K-dependent coagulation parameters assessed in the first hour after birth did not differ between
VKORC1-wildtype infants and those carrying -1639A alleles.
Conclusions: Our data support the assumption that genetic variants in the vitamin K-dependent coagulation system
influence the coagulation profile and the IVH risk in preterm infants. Further studies focussing on short-term changes
in vitamin K-kinetics and the coagulation profile during the first days of life are required to further understand a
possible link between development of IVH and genetic variants affecting the vitamin K-metabolism.
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Intraventricular hemorrhage (IVH) is a serious compli-
cation in very low birth weight (VLBW) infants and is
strongly associated with neuro-developmental deficits
and long-term disability in the surviving infants [1]. A
large study on 450 twin-pairs estimated the contribution
of genetic and shared environmental factors to the risk
of developing IVH at 41% [2]. Considering the immatur-
ity of the preterm infants’ coagulation system, genetic
variants known to be associated with alterations in the
coagulation profile in adults have been subject to various
association studies in preterm infant cohorts. However,* Correspondence: Axel.Heep@bristol.ac.uk
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unless otherwise stated.most of them focused on prothrombotic mutations, of
which the factor V Leiden mutation and the prothrom-
bin G20210A variant were linked to the individual risk
to develop IVH [3-6]. On the other hand, studies analyz-
ing variants affecting the vitamin K dependent coagula-
tion system in preterm infant cohorts are scarce [7].
Vitamin K is an essential cofactor in the posttransla-
tional carboxylation converting intracellular precursors
of vitamin K dependent coagulation factors to their
active forms. During this carboxylation, the active coen-
zyme form of vitamin K, hydroquinone, is oxidized to
vitamin K epoxide. Subsequently, the vitamin K epoxide
reductase (VKORC1) reduces the epoxide form back to
the active hydroquinone [8]. The promoter region of the
VKORC1 gene harbours a single nucleotide polymorph-
ism (SNP) -1639G>A, which has been associated with a
reduction in VKORC1 enzyme expression of up to 50%al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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oral anticoagulants, which act via inhibition of VKORC1,
and has been reported to explain 27% of warfarin dosing
variability [10].
Another functional relevant polymorphism has been
detected in the gene of the vitamin K dependent
clotting factor VII. The insertion of a decanucleotide
at position −323 in the promotor region is associated
with reduced promotor activity and decreased factor
VII levels in vitro and in vivo [11,12]. Ito et al. analyzed
the coagulation profile of 200 Japanese children at the
age of one month and demonstrated 25% lower coagula-
tion ability in carriers of the insertion variant [13].
The aim of our study was to determine the impact of
the polymorphism VKORC1-1639G>A and F7-323Ins10
on the coagulation profile and IVH risk in preterm in-
fants less than 32 weeks of gestational age.
Methods
Study cohort and clinical definitions
Between May 2008 and February 2010, 124 preterm
infants with a gestational age of less than 32 weeks of
gestational age were born at the perinatal center of
the University Hospital of Bonn. 34 infants were not
included based on the following criteria: congenital mal-
formation, chromosomal abnormalities, cholestatic liver
disease, virus hepatitis, congenital heart defects, and
prenatal diagnosis of intraventricular hemorrhage and
periventricular leucomalacia. The final study population
comprised 90 infants. By reviewing birth protocols and
medical charts of the patients, we collected relevant clin-
ical data including gender, gestational age, auxological
birth parameters, mode of delivery, prenatal steroids,
Apgar-Score, Clinical Risk Index for Babies (CRIB)-Score
and mean arterial blood pressure at admission to our
neonatal intensive care unit (NICU). Small for gestational
age (SGA) was defined as birth weight and/or length
below the 3rd centile. Gestational age was determined by
first trimester ultrasound examination. Clinical chor-
ioamnionitis was defined by CRP value in the maternal
serum of >20 mg/l, maternal leukocyte count >15,000/μl
and fever >38°C on the last three days before delivery.
Respiratory support via continuous positive airway
pressure (CPAP) as well as intubation and mechanical
ventilation were categorized positive when required
within the first five days. The parameter surfactant
included different modes of surfactant application within
the first day of life via either endotracheal tube, Insure
Sequence (intubate, surfactant, extubate) or via gastric
tube placed intratracheally in infants receiving respira-
tory support by CPAP. Catecholamine treatment of arter-
ial hypotension (categorized positive when needed within
the first 72 hours) followed a standardized protocol. In
addition to the incidence of a patent ductus arteriosus,we separately assessed administration of indomethacin or
ibuprofen and surgical closure. All clinical data were
anonymized prior to statistical analyses.
The diagnosis of intraventricular hemorrhage was based
on serial ultrasound examinations (8.5-10 MHz trans-
ducer, Vingmed Vivid FiVe and Philips HD7 respectively)
on days 1, 3 and 7 postnatal age. The maximal grade of
IVH was confirmed by cranial ultrasound on day 7 post-
natal age. IVH grade I was defined as bleeding into the
germinal matrix, grade II as blood within the ventricular
system filling less than 50% of the ventricular volume and
without distension, grade III as blood in the ventricular
system with distension or dilatation, and grade IV as
bleeding with parenchymal involvement [14].
Coagulation profiles
Citrate blood samples for coagulation profile analyses were
collected together with the routine laboratory testing for
blood count, C-reactive protein (detection limit 0.2 mg/l)
and interleukin 6 within the first hour of life prior to vita-
min K administration (0.2 mg phytomenadione solution
intravenously). Determined components of the coagulation
profile included activities of clottable fibrinogen, activity of
coagulation factors II, V, VII, VIII, and X, as well as anti-
thrombin. Coagulation parameters were analyzed in the
platelet poor plasma after centrifugation, the remaining
sediment was used for DNA extraction. Details on blood
sampling and laboratory methods used to determine con-
centrations and activities of the above-mentioned coagula-
tion parameters are described elsewhere [15].
Genotyping
In order to minimize the required total blood volume
taken for study purposes, DNA for genotyping was
extracted from remaining citrate blood sediments using
a commercially available kit (Invitrogen, Carlsbad, USA).
Genotypes for the polymophisms VKORC1 -1639G>A
(rs9923231) and factor 7 -323Ins10 (rs36208070) were
determined by PCR-restriction fragment length poly-
morphism analysis. PCR primer sequences and reaction
conditions are available on request. Genotyping was suc-
cessful in 87 of 90 samples for the VKORC1-polymorph-
ism and in 86 samples for F7 -323Ins-polymorphisms.
250 healthy adult blood donors, who were previously
genotyped at the Institute of Experimental Hematology
and Transfusion Medicine, University of Bonn, served as
reference population [16].
Statistical analysis
Data were analyzed using the SPSS version 21.0 (SPSS
Inc., Chicago, IL, USA). A p-value <0.05 was considered
statistically relevant. To compare values between geno-
type groups and between infants with and without IVH,
we used Mann–Whitney U- and Fisher’s exact tests.
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independent risk factors for the development of IVH.
Because of the small number of samples homozygous
for the variant allele of both polymorphisms, those
heterozygous and homozygous for the variant allele were
grouped for statistical analysis.
Ethics
Written informed consent was obtained from all parents.
The study was approved by the Ethics committee of the
Medical Faculty of the University of Bonn (048/08).
Results
90 preterm infants with a gestational age of less than
32 weeks born in the perinatal center of the University
Hospital of Bonn between May 2008 and February 2010
were included in this prospective cohort study. IVH oc-
curred in 17 infants (18.9%). Clinical characteristics and
routine laboratory parameters of the study population
are summarized in Table 1. Infants who developed an
IVH were born at a significantly lower gestational age,
were more frequently intubated and mechanically venti-
lated, and received less frequently respiratory support by
CPAP compared to those without IVH. More also re-
quired surgical closure of patent ductus arteriosus. Com-
parison of laboratory parameters revealed significantly
lower levels of the vitamin K-dependent coagulation
factors II and X in the IVH group (Table 1). Clinical data
stratified for F7-323Ins10 and VKORC1 -1639G>A poly-
morphisms are presented in Tables 2 and 3.
Allele frequencies for the polymorphisms F7-323Ins10
(wt/wt 79.1%, wt/-323Ins10 20.9%) and VKORC1 -1639G>A
(GG 39.1%, GA 46.0%, AA 14.9%) were in Hardy-Weinberg
equilibrium and comparable with those reported pre-
viously [16,17].
Infants carrying the F7-323Ins10 variant tended to
have lower FVII levels compared to wildtype infants.
The genotype effect on FVII levels became statistically
significant after adjustment for gestational age (p = 0.028).
Similarly, F7-323In10 carriers also showed lower FX levels
after adjusting for gestational age. All other clinical and
laboratory parameters including occurrence of IVH did not
differ between wildtype infants and those carrying at least
one F7-323Ins10 allele (Table 2).
Apart from a trend towards lower gestational age,
VKORC1 -1639A carriers revealed higher C-reactive pro-
tein (mean 4.8 ± 13.3 mg/l vs. 1.9 ± 8.7 mg/l; p = 0.031) and
lower hematocrit levels (mean 47.1 ± 9.8% vs. 43.5 ± 8.8%;
p = 0.047) in our cohort (Table 3). The genotype effects on
C-reactive protein and hematocrit disappeared after adjust-
ment for gestational age (both p > 0.2). Other laboratory
parameters including plasma levels of the vitamin K
dependent coagulation factors as determined in the first
hour of life did not differ significantly between genotypegroups. However, VKORC -1639A carriers were less likely
to suffer from IVH (GG 26.5%, GA 15.0%, AA 7.7%;
p = 0.019 after adjusting for gestational age). Logistic
regression analysis including the variables gestational
age, 5 minute Apgar score, intubation, incidence of a
patent ductus arteriosus, hematocrit, and VKORC1-
genotype revealed significant contributions of gestational
age (OR 0.93 per day (95% CI 0.89-0.98), p = 0.004),
and VKORC1 -1639A carrier status (OR 0.20 (95% CI
0.05-0.80), p = 0.024) to the individual IVH-risk. Figure 1
illustrates the distribution of IVH cases according to
VKORC1-genotype and gestational age.
Discussion
In the present study we assessed the impact of two
polymorphisms in the vitamin K dependent coagulation
system on the coagulation profile and the occurrence of
IVH in preterm infants with a gestational age of less
than 32 weeks. Consistent with previously published
data obtained from adults [18] and one-month-old chil-
dren [13], carriers of the F7-323Ins10 allele showed
lower levels of FVII. In adults, a large case–control study
comparing 201 patients with spontaneous intracranial
hemorrhage and 201 control subjects revealed a 1.54-
fold risk for intracranial hemorrhage in carriers of
the -323Ins10 allele [19]. The importance of FVII ac-
tivity for the perinatal coagulation status and morbidity
is further demonstrated in f7−/− mice who suffer from
fatal perinatal bleeding: 70% of them have fatal intra-
abdominal bleeding within the first day of life, whereas
most of the remaining neonates die from intracranial
hemorrhage before the age of 24 days [20]. However, in
our cohort we did not observe an association between
the F7-323Ins10 polymorphism and occurrence of IVH.
This is in line with data from a large genotype associ-
ation study comprising 1009 VLBW infants [7].
In contrast to our previously published data [21], we
did not find an association of early postnatal FVII levels
and occurrence of IVH in the current cohort. However,
apart from a smaller sample size (90 vs. 132 infants) and
probably not sufficient statistical power to detect com-
paratively small effects, these two cohorts are not
comparable. Whereas the previously reported cohort
comprised exclusively extremely preterm infants with
less than 28 weeks of gestational age (n = 132), only
48.9% (n = 38) of the current cohort were born with a
gestational age below 28 weeks. Accordingly, total IVH
rates differed markedly (43.9% vs. 18.8%), reflecting the
close relationship between gestational age and risk to
develop IVH. In addition, we and others have demon-
strated a significant inverse relationship between factor
VII levels and gestational age [15,22,23], and at least
in extremely preterm infants with correspondingly im-
mature coagulation profiles, low factor VII levels may
Table 1 Neonatal data and routine laboratory at the first day of life according to the diagnosis of IVH confirmed by
ultrasound at the 7th day of life (median with range and percentages, respectively)
Total (n = 90) Non-IVH (n = 73) IVH (n = 17) p-value
Gestational age [weeks + days] 28 + 0 (23 + 3 -31 + 5) 28 + 3 (24 + 0 - 31 + 5) 27 + 0 (23 + 3 - 30 + 2) 0.016
Birth weight [g] 990 (320 – 2270) 990 (400 – 2270) 920 (320 – 1495) 0.248
Male [%] 67.8 67.1 70.6 1.000
SGA [%] 18.9 19.2 17.6 0.727
Prenatal steroids [%] 67.4 68.1 64.7 0.781
AIS [%] 5.6 5.5 5.9 1.000
Cesarean section [%] 98.9 98.6 100 1.000
Surfactant [%] 83.3 79.5 100 0.065
RDS [%] 85.6 84.9 88.2 1.000
RDS [median grade] 2 2 2 0.549
CPAP [%] 88.9 93.2 70.6 0.019
Intubation [%] 41.1 34.2 70.6 0.012
PDA [%] 75.6 71.2 94.1 0.061
PDA medicament [%] 78.9 75.3 94.1 0.108
PDA OP [%] 5.6 2.7 17.6 0.045
Sepsis [%] 10.0 6.8 23.5 0.061
Catecholamines [%] 42.2 38.4 58.8 0.173
umbilical artery pH 7.33 (7.15 - 7.52) 7.33 (7.15 - 7.52) 7.34 (7.22 - 7.38) 0.530
Apgar 5 min 8 (2–10) 8 (2–10) 8 (6–9) 0.183
CRIB-Score 2.5 (0–16) 2.0 (0–14) 5.0 (1–16) 0.495
Mean arterial pressure [mmHg] 33.5 (19–60) 34.0 (20–60) 27 (19–42) 0.053
Hematocrit [%] 45.0 (10.7 - 59.0) 47.0 (10.7 - 59.0) 41.0 (24.0 - 59.0) 0.075
Leucocytes [×103/μl] 7.24 (1.08 - 32.00) 7.39 (1.08 - 32.00) 6.63 (1.16 - 26.25) 0.613
Thrombocytes [×103/μl] 160 (15–291) 150 (15–272) 175 (30–291) 0.270
Il-6 [pg/ml] 51.6 (2.0 - 689,002.0) 42.3 (2.0 - 57,050.0) 92.1 (12.9 - 689,002.0) 0.197
CRP [mg/l] 0.2 (0.2 - 78.2) 0.2 (0.2 - 78.2) 0.2 (0.2 – 20.9) 0.461
FII [activity in%] 32 (17–65) 35 (17–65) 27 (18–36) 0.001/*0.006
FVII [activity in%] 31 (7–93) 31,5 (7–93) 29 (10–48) 0.116/*0.281
FX [activity in%] 41 (14–89) 46 (14–89) 33 (24–62) 0.007/*0.023
ATIII [activity in%] 30 (13–51) 30.0 (13–51) 28 (13–45) 0.241/*0.383
*adjusted for gestational age.
Definitions: Antenatal steroids: maternal Betamethason treatment 2x 12 mg (i.v.) > 24 prior delivery; AIS: Chorioamnionitis: clinical diagnosis of chorioamnitis
(maternal temperature > 38° Celsius, leucocytosis > 15,0000, CRP > 20 mg/l); SGA: birth weight < 3rd centile; Catecholamine treatment (n = 130): any catecholamine
treatment (Dopamine, Dobutamine, Epinephrine) to maintain blood pressure > 10th centile < 72 hours postnatal age.
Bold numbers are used for results reaching statistical significance.
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ment of IVH [15].
Interestingly, F7-323Ins10 carriers also showed lower
FX levels after adjusting for gestational age. Considering
the close proximity of the genes encoding the coagula-
tion factors VII and X on chromosome 13q34, linkage of
functionally relevant polymorphisms in these two genes
may explain this finding.
VKORC1 is considered the key protein of the vitamin
K cycle. Its physiological relevance during early stages oflife is highlighted by the phenotype of vkorc1−/− mice
who develop normally until birth, but die within 2 to
20 days after birth due to extensive, predominantly
intracerebral hemorrhage. The lethal phenotype, which
results from severe vitamin K-dependent clotting factor
deficiency, can be rescued by oral administration of vita-
min K [24]. Similar to vkorc1−/−mice, patients suffering
from vitamin K-dependent clotting factor deficiency type 2,
an extremely rare autosomal recessive bleeding disorder
arising from point mutations in the VKORC1 gene, also
Table 2 Neonatal data and routine laboratory at the first day of life according to F7-genotype (median with range and
percentages, respectively)
F7-323Ins10 wildtype (wt/wt) (n = 68) F7-323Ins10 carrier (wt/10 + 10/10) (n = 18 + 0) p-value
Gestational age [weeks + days] 27 + 6 (23 + 3 - 31 + 5) 28 + 5 (25 + 2 - 30 + 6) 0.656
Birth weight [g] 990 (320–2005) 990 (405–2270) 0.255
Male [%] 66.2 73.7 0.593
IVH [%] 18.3 21.1 0.750/*0.649
Prenatal steroids [%] 65.7 73.7 0.591
Surfactant [%] 81.7 89.5 0.729
CPAP [%] 87.3 94.7 0.682
Intubation [%] 40.8 42.1 1.000
PDA medicament [%] 77.5 84.2 0.753
PDA OP [%] 7.0 0.0 0.580
Sepsis [%] 11.3 5.3 0.678
Apgar 5 min 8 (5–10) 8 (2–9) 0.444
CRIB-Score 4 (0–16) 1.5 (1–8) 0.108
Il-6 [pg/ml] 42.3 (2.0 - 689,002.0) 102.0 (10.5 - 5140.0) 0.326
CRP [mg/l] 0.2 (0.2 - 78.2) 0.2 (0.2 - 35.0) 0.917
Hematocrit [%] 46.0 (10.7 - 59.0) 43.0 (31.0 - 59.0) 0.452
Leucocytes [×103/μl] 7.08 (1.08 - 32.00) 7.70 (3.29 - 26.25) 0.353
Thrombocytes [×103/μl] 157 (15–278) 170 (75–291) 0.174
FII [activity in%] 34 (17–65) 29 (23–45) 0.236/*0.107
FVII [activity in%] 34 (7–93) 29 (12–48) 0.052/*0.028
FX [activity in%] 45 (23–89) 33 (14–58) 0.340/*0.013
ATIII [activity in%] 30 (13–51) 29.5 (16–48) 0.903/*0.799
*adjusted for gestational age.
Bold numbers are used for results reaching statistical significance.
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[25,26]. Considering the decreased enzyme activity and
warfarin dose requirement resulting from the relatively
frequent VKORC1 -1639G>A polymorphism, one may
speculate that the variant allele (−1639A) might be
associated with a higher risk of developing IVH. Con-
versely, we found a higher IVH risk in VKORC1-1639GG
homozygotes compared to infants with at least one
A-allele. A possible explanation might be the reported
alteration of the vitamin K pharmacokinetics mediated
by VKORC1 -1639G>A. In a pilot study comprising
five men and five women each per genotype group,
VKORC1-1639GG homozygotes exhibited a signifi-
cantly shorter elimination half-time of orally adminis-
tered vitamin K1 compared to carriers of at least one
A-allele [27]. Moreover, in a cohort of 202 adult patients
receiving warfarin treatment, the required warfarin dose
was significantly reduced in association with decreasing
dietary vitamin K intake in VKORC1-1639AG heterozy-
gotes. This dietary influence was totally abolished in
VKORC1-1639AA homozygotes [28]. In another study
on 33 over-anticoagulated adult patients, the INR valuedecreased significantly faster in carriers of the G allele
compared to VKORC1-1639AA homozygotes [29]. How-
ever, the impact of VKORC1-1639G>A on vitamin K
pharmacokinetics in the pediatric population has, to our
knowledge, not been investigated so far. This is of par-
ticular clinical importance since preterm infants have a
substantially diminished coagulation profile compared to
adults [15,22,23] and probably also differ with regard to
the pharmacokinetics of vitamin K [30]. Consequently,
the higher IVH rate observed in -1639GG infants might
be directly linked to genotype effects on vitamin K me-
tabolism and related short term changes in the coagula-
tion profile following the routinely administered vitamin
K prophylaxis on the first day of life.
In the present cohort, levels of the vitamin K
dependent clotting factors did not differ according to
the VKORC1 -1639G>A genotype. However, it is import-
ant to note that all laboratory parameters were assessed
in the first hour of life. Presuming that pharmacokinetics
of vitamin K depend on VKORC1 -1639G>A, plasma
levels of the vitamin K dependent clotting factors might
develop differently in the course of the following hours
Table 3 Neonatal data and routine laboratory at the first day of life according to the VKORC1-genotype (median with
range and percentages, respectively)
VKORC1-1639G>A wildtype (GG) (n = 34) VKORC1-1639G>A carrier (GA + AA) (n = 40 + 13) p-value
Gestational age 28 + 6 (24 + 0 – 31 + 5) 27 + 4 (23 + 3 – 31 + 1) 0.057
Birth weight [g] 1037.5 (410 – 2005) 915 (320 – 2270) 0.095
Male [%] 67.6 69.8 1.000
IVH [%] 26.5 13.2 0.158/*0.019
Prenatal steroids [%] 64.7 69.2 0.814
Surfactant [%] 82.4 83.0 1.000
CPAP [%] 94.1 86.8 0.473
Intubation [%] 44.1 39.6 0.824
PDA medicament [%] 79.2 76.5 0.795
PDA OP [%] 5.9 5.7 1.000
Sepsis [%] 11.8 7.5 0.706
Apgar 5 min 8 (2 – 9) 8 (5 – 10) 0.062
CRIB-Score 2 (0 – 14) 3.5 (0 – 16) 0.166
Il-6 [pg/ml] 35.0 (3.8 – 775.0) 55.6 (2.0 – 57,050.0) 0.388
CRP [mg/l] 0.2 (0.2 – 51.1) 0.2 (0.2 – 78.2) 0.031/*0.271
Hematocrit [%] 46 (10.7 – 59.0) 44 (15.2 – 59.0) 0.047/*0.268
Leucocytes [×103/μl] 7.28 (1.98 – 32.00) 7.30 (1.08 – 26.25) 0.889
Thrombocytes [×103/μl] 165 (29 – 235) 160 (15 – 291) 0.258
FII [activity in%] 29.5 (20 – 53) 33 (17 – 65) 0.495/*0.154
FVII [activity in%] 30.5 (13 – 93) 31 (7 – 69) 0.868/*0.330
FX [activity in%] 37.5 (24 – 73) 44 (14 – 89) 0.682/*0.235
ATIII [activity in%] 29 (13 – 51) 29.5 (13 – 48) 0.903/*0.532
*adjusted for gestational age.
Bold numbers are used for results reaching statistical significance.
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to develop IVH. Further research is required to assess the
impact of the VKORC1 -1639G>A polymorphism on
vitamin K pharmacokinetics and the coagulation profile
in extremely preterm infants with a high risk to develop
IVH. In this context, it seems advisable to re-evaluate
dose, interval and route of the routine vitamin K admin-
istration in this particular group of neonates.Figure 1 Distribution of IVH cases according to VKORC1-genotype anConclusion
In the present study, we assessed the impact of func-
tional polymorphisms in the F7 and VKORC1 genes on
the coagulation profile and the risk to develop IVH in a
cohort of preterm infants. Our data support the assump-
tion that genetic variants in the vitamin K-dependent
coagulation system influence the coagulation profile and
the IVH risk in this particular group of neonates with and gestational age.
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http://www.biomedcentral.com/1471-2431/14/219increased risk of developing IVH. Further studies focus-
sing on vitamin K kinetics and short-term changes in
the coagulation profile, particularly during the first days
of life, are required to further understand a possible link
between IVH risk and genetic variants affecting the
metabolism of vitamin K.
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